Table 1 Characteristics of the PPH trials
From: The early outcomes of candidates with portopulmonary hypertension after liver transplantation
References | Institute | Sample size | Study periods | Recipients age | MELD score | NOS star level | ||
|---|---|---|---|---|---|---|---|---|
PPH | No-PPH | PPH | No-PPH | |||||
DeMartino(2017) [4] Rajaram(2016) [13] | USA(single center) USA(single center) | 31 13 | 269 20 | 2010–2013 2005–2015 | 57 (50–62) 52(37–62) | 32 (25–38) 21.0 ± 9.2 | 25 (20–29) 24.7 ± 9.5 | 66 |
Bozbac(2015) [17] Salgia (2014) [6] Mangus(2013) [16] | Turkey(single center) SRTRa USA(single center) | 47 78 102 | 156 34,240 1161 | 2004–2015 2002–2010 2001–2010 | 42.1 ± 14.1 54 (49–60) 53 (18–76) | N/Ab 14 (11–18) 22(9–40) | N/A 18 (13–25) 18 (6–40) | 6 6 7 |
Yassen(2012) [15] ▲ Pietri(2010) [14] Saner (2006) [7] | Egypt(single center) Italy(single center) Germany(single center) | 9 24 23 | 10 24 48 | 2008–2011 2003–2008 2004–2005 | 50.3 54(49–60) 49.6 | 17 ± 5 25.0 ± 12.0 N/A | 14 ± 2 22.0 ± 10.9 N/A | ◆5 6 6 |
Veloso(2004) [21] Starkel (2002) [18] Ramsay(1997) [32] Taura(1996) [19] | Brazil(single center) UK(single center) USA(single center) Spain(single center) | 31 38 103 8 | 26 107 1103 15 | 1999–2001 1997–1999 1984–1995 N/A | 46 49.2 N/A 45.2 | N/A N/A N/A N/A | N/A N/A N/A N/A | 6 6 5 5 |